CA-EYENUK
16.5.2019 09:07:04 CEST | Business Wire | Press release
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.
At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.
“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”
About 7.5 million people in Germany have diabetes mellitus2 , with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.
“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5
While DR screening is recommended for all diabetic patients, less than half get screened annually1 , even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6 , there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt is a registered trademark of Eyenuk Inc.
____________________
| 1 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 2 |
International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas |
|
| 3 |
https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611 |
|
| 4 | Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909 | |
| 5 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 6 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005207/en/
Contact:
Media Contact: Capwell Communications Ida Yenney ida@capwellcomm.com 949-999-3303
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom